News – USA – CTXR Stock Price Soaks Over 10% Ahead Of Market: Why It Happened


Citius Pharmaceuticals Inc (NASDAQ: CTXR) – a specialty pharmaceutical company focused on developing and marketing critical care drugs – will be over 10% prior to going public as of 6:58 a.m. ET traded Investors are reacting to the announcement by Citius Pharmaceuticals, the already announced sale of a total of 50830566 ordinary shares and the associated warrants to purchase a total of 25415Having completed 283 shares of common stock at a purchase price of $ 1505 per share and associated warrant in a registered direct offering at market price under Nasdaq rules

The warrants have an exercise price of USD 70 per share and are immediately exercisable and expire five years after the issue date

The total gross proceeds of the offer to the company are approx $ 765 million, prior to the deduction of agency fees and other offering costs payable by the company, and Citius currently intends to use the net proceeds from the offering for general corporate purposes, including the preclinical and clinical development of our product candidates, as well as working capital and capital expenditures

Disclaimer: This content is provided for informational purposes before making any investment, it is recommended that you do your own analysis

Citius Pharmaceuticals, NASDAQ: CTXR, Nasdaq, Pharmaceutical Industry, Stock

News – USA – CTXR share price rises over 10% ahead of the market: Why it happened
Related Title :
CTXR share price rises over 10% before it is placed on the market: Why it happened
Technical data drives growth: Citius Pharmaceuticals Inc (CTXR), Birks Group Inc (BGI)
> What does Citius Pharma expect in 2021?